Biotechnology demystifies cataracts

This book explores an innovative approach to treating cataracts by replacing denatured crystallins with genetically engineered normal crystallins. It details the role of disulfide bridges in the stability of crystalline proteins and their link to the denaturation that leads to cataracts. Introducing lens regeneration, the book discusses the recombinant production of crystallins, via genetic cloning and expression in various biological systems. The technical challenges of implanting these recombinant crystallins into the lens are also analyzed, including compatibility, stability and long-term safety. The book concludes with a look at the future prospects of this technology, including its potential for treating other protein pathologies and its impact on regenerative medicine. This approach could revolutionize cataract treatments and open up new avenues for regenerative therapies in other biomedical fields.